CS Paper Radar

Towards AI-Assisted Clinical Trial Matching: Practical Considerations, Multicenter Evaluation, and Real-World Deployment

Yin Fang, Qiao Jin, Shubo Tian, Lauren He, Maya Geer, Noor Naffakh, Ryan Huu-Tuan Nguyen, Zifeng Wang, Jimeng Sun, Charalampos S. Floudas, James L. Gulley, Kamilia Moalem, Catarina Martins Maia, Amanda Nottke, Juan W. Valle, Melinda Bachini, Lourdes Rocha-Nussbaum, Kari Ramage, Nikita Curry, Megan Barnes, Mandy Mansaray, Darlene Gabeau, Craig E. Grossman, Heath Skinner, Michael Burczynski, NIH-TrialBench Consortium, Zhiyong Lu

cs.CL cs.AIcs.CY ·submitted 2026-09-01 13:11 UTC · v2
benchmark

Abstract

Clinical trials are essential for evidence-based medicine and drug development, but many fail because of insufficient patient enrollment. Although there is growing interest in using AI to support patient recruitment, existing systems largely perform eligibility assessment alone and have rarely been evaluated in real-world workflows. Here we present TrialGPT 2.0, an AI-assisted clinical trial recommendation system improved for responsible real-world deployment. Rather than asking only whether a patient may qualify, the system assesses which trials warrant further consideration given the patient's current clinical needs and local workflow priorities, and provides structured, inspectable explanations for expert review. Importantly, we evaluated TrialGPT 2.0 retrospectively and prospectively across government research, patient-advocacy, academic medical center, and community-based radiation-oncology settings. In retrospective multicenter cohorts comprising 288 cases, TrialGPT 2.0 retrieved at least one clinician-recommended trial in its top 10 recommendations for approximately 91% of cases while reducing clinician screening time by 55.0%. In a six-month prospective evaluation embedded in an active precision oncology tumor board, TrialGPT 2.0 contributed additional trial opportunities missed by the routine workflow, increasing the number of patient cases with at least one final trial recommendation by 90.9%. To support scientific reproducibility, we also developed NIH-TrialBench, a clinician-authored benchmark comprising 126 diverse synthetic patient vignettes and matching scenarios from 11 NIH Institutes and Centers. Together, these findings support the value of AI to assist clinical trial matching by improving clinician efficiency and identifying frequently overlooked trial opportunities, ultimately helping to expand and accelerate accrual to cancer trials.

Comment
43 pages, 12 figures

Closest papers

Nearest neighbours by meaning across the whole index.

TrialDesignBench: Benchmarking Language Models for Phase-I Trial Design Against Clinical Knowledge

cs.AI cs.CLstat.AP ·2026-11-09 ·Yihan Hank Tang, Peng Yang, Jiayi Xin, Tianqi Shang, Xuyang Chen +3 more
publishedbenchmarkcode/data similarity 0.66
Abstract · 13 pages, 3 figures, 6 tables. Presented as a poster at the NeurIPS 2026 Workshop on World Models for High-Stakes Health (WMHS). Code and da…

AI is used in much of the clinical trial pipeline. However, selecting the statistical design of a trial, a crucial step that determines how drug doses are tested on humans and evaluated, has seen almost no AI progress. LLMs appear to be a natural fit given their strengths in biomedical knowledge and statistical reasoning. Nevertheless, there is currently no appropriate way to evaluate such abilities because recent regulatory and methodological shifts, most notably FDA's Project Optimus, have redefined what constitutes a reasonable design and rendered many previous designs obsolete. To lay the groundwork for AI-assisted trial design, we introduce TrialDesignBench, a benchmark of 617 Phase-I/I-II oncology dose-finding trials, each paired with an expert-validated reference design that is consistent with the latest FDA regulatory initiatives. This reference standard is produced through a formalization of the expert design process. We evaluate five frontier LLMs, none of which matches the reference standard. Our ablation experiments trace this performance gap to two main causes, inference of latent, unrecorded design determinants from trial sources (supplying them raises class-wise balanced accuracy by 0.22) and structured decision-tree reasoning (+0.24). TrialDesignBench offers a reproducible, contemporary-standard objective for evaluating and enhancing AI-assisted trial design.

0.45

Scaling large language model-assisted line-of-therapy adjudication with human-in-the-loop evidence-calibrated selection

cs.LG q-bio.QMstat.AP ·2026-11-15 ·Olatunji Oni, Sanhita Sengupta, Marc De Benedetti, Nathanial Eddy
similarity 0.66
Abstract · 12 pages, 4 figures

Large language models (LLMs) have enabled the ability to scale clinical adjudication tasks traditionally dependent on exhaustive manual review. Line-of-therapy (LoT) adjudication, a major bottleneck in oncology cohort construction, is a prime example. Line boundaries must be inferred from longitudinal treatment histories according to nuanced, study-specific definitions, at every regimen transition for every patient. LLMs can apply this adjudication at scale, but their reliability varies across patients. Treatment histories differ in complexity, and ambiguous or atypical patterns depend on expert clinical judgment. Reliable automation thus requires verified support for model assignments and the ability to identify cases that warrant manual review. Here, we present evidence-calibrated selection (ECS), a human-in-the-loop framework for scaling LLM-assisted LoT adjudication. ECS derives confidence from observed clinician adjudications, prioritizes patients with the least-supported assignments for follow-up review, and returns completed adjudications to the model as precedent. As the evidence base grows, ECS continuously calibrates confidence to estimate residual error, thus enabling more efficient use of clinician time. In simulations on 136 clinician adjudicated patients with multiple myeloma, ECS achieved a residual error of 5% after review of 44.6% of patients, compared to 62.2% when review was directed by LLM self-reported confidence and 81.9% under random sampling. These results support a scalable approach to study-specific LoT adjudication, using clinician evidence to inform automated predictions, minimize error, and reduce review burden.

0.21

RECITE: Revising Eligibility Criteria Incorporating Textual Evidence

cs.AI ·2026-10-30 ·Russell Ro, Reza Abbasi-Asl
top venuebenchmark similarity 0.62
Abstract · 18 pages, 4 figures, 4 tables. Extended version of a paper in KDD 2026 (32nd ACM SIGKDD Conference on Knowledge Discovery and Data Mining). …

Overly restrictive eligibility criteria contribute to widespread enrollment failure in clinical trials, yet published recommendations for how specific criteria should be broadened remain disconnected from trial design at scale. We introduce RECITE (Revising Eligibility Criteria Incorporating Textual Evidence), a framework for automated discovery, extraction, and implementation of evidence-based eligibility criteria revisions. RECITE uses protocol amendment documents from ClinicalTrials.gov to construct a dataset of 11,913 curated instances across 5,735 trials, each pairing original criteria with documentary evidence and target revisions. We benchmark fifteen LLM configurations under truncated-to-context-window and retrieval-augmented generation conditions, on a 3,116-instance sample under an LLM-as-judge protocol validated against ten domain experts (judge vs. human quadratic-weighted Cohen's $κ_{qw} = 0.694 \pm 0.096$). The best open-weight model, Gemma 2 9B, achieves $κ_{qw}$-aligned ordinal score $3.0 \pm 0.9$ on a 0--4 scale (normalized 0.742) and the best closed-weight model, GPT-4o, reaches $3.0 \pm 0.8$ (normalized 0.745). Using an agentic literature discovery system, we then identified 44 paper--trial matches across five publications providing trial-design and EC-modification evidence. Our findings suggest that existing clinical knowledge can be operationalized into actionable trial design recommendations.

0.55

OpenMTB-Audit: Exposing Over-Refusal and Clinical Expert Perspectives in LLM-Based Molecular Tumor Board Safety Evaluation

cs.AI cs.LG ·2026-10-01 ·Negin Ashrafi, Jia Luo, Stacey M. Frumm, Roxana Daneshjou
publishedbenchmarkcode/data similarity 0.62
Abstract · Accepted for oral presentation and publication at the Pacific Symposium on Biocomputing (PSB) 2027

Molecular tumor boards integrate genomic findings, clinical context, and therapeutic evidence to support precision oncology. As AI enters this workflow, a key safety challenge is distinguishing truly unsupported recommendations from evidence-supported options that still require oncologist review because of incomplete information, poor ECOG performance status, or other clinical caveats. We introduce OpenMTB-Audit, an open-source benchmark of 500 synthetic non-small cell lung cancer cases spanning five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. Across eight large language model configurations, we identify pervasive over-refusal: all LLM configurations failed to retain the Partially Supported label in 83.3-100% of true Partially Supported cases, achieving high aggregate safety scores through label collapse rather than clinically calibrated reasoning. To address this limitation, we developed MTB-AuditAgent, a deterministic seven-module framework separating evidence verification, missing-information detection, safety classification, and abstention. It reduces over-refusal to 6.7% and achieves 91.2% accuracy (95% CI: 88.6-93.6%). A two-oncologist annotation study found disagreement concentrated at the boundary between information sufficiency and treatment optimization, underscoring the need to preserve clinically meaningful distinctions.

0.57

An Evidence-Driven Multi-Agent Compound AI System for Head and Neck Proton Radiotherapy Planning

cs.AI ·2026-10-21 ·Qingqing Wang, Liqiang Xiao, Chang Chang
similarity 0.62
Abstract

Radiation treatment planning requires balancing competing objectives to satisfy clinical criteria while accommodating physicians' preferences. This study aims to develop an evidence-driven, multi-agent compound AI system that integrates DRL-based automated treatment planning with LLM-based conversational plan refinement for proton PBS therapy. A policy network trained using PPO first generates multiple plans without human intervention, from which one is selected as the target plan and the others serve as references for subsequent refinements. For challenging cases requiring further adjustments, an LLM-based multi-agent system enables plan refinement through natural language interactions. The system comprises a planning agent that recommends evidence-supported adjustments, a chatbot providing a unified conversational interface, and an evaluation agent that retrieves clinical metrics and identifies constraint violations. To enhance domain-specific reasoning, the planning agent based on Qwen3-14B is designed to justify its recommendations using evidence from previously generated plans and post-trained on task-specific data using SFT and GRPO. The framework was trained and evaluated using 21 patients with H&N cancers, with 5 PPO-generated plans per patient. Of these, 50 plans were selected for instruction-guided refinement. Compared with the base LLM, the post-trained Qwen3-14B demonstrated improved instruction-following, information retrieval and domain-specific reasoning capabilities. The resulting adjustments more effectively improved user-prioritized objectives while limiting deterioration in competing objectives, yielding more clinically appropriate trade-offs in patient-specific plan refinement. The proposed compound AI system provides a user-friendly planning platform, offering a promising approach to personalized proton PBS treatment planning.

0.11

VirtualTrialHarness: Coordinating Agentic Operationalization of Virtual Trial Protocols Across Complex Clinical Schemas

cs.AI ·2026-11-03 ·Pengze Li, Jingna Feng, Yue Yu, Yining Wu, Xinyue Hu +3 more
similarity 0.62
Abstract

Virtual trials use routinely collected clinical data to evaluate treatment strategies, but translating a study protocol into an executable analysis requires determining how clinical concepts and study requirements should be represented in the available data and applied consistently across the workflow. These decisions depend on local data representations and operational conventions and can involve source selection, patient and encounter identity, linkage, and temporal interpretation. Here we introduce VirtualTrialHarness (VTHarness), an agent framework that coordinates virtual-trial operationalization by selecting reusable procedural skills for each workflow stage and uses explicit contracts to maintain consistent study decisions across stages. We also introduce VTBenchmark for evaluating source selection and cohort construction. Across three complex synthetic environments, VTHarness successfully produced all required cohort outputs matching the references in 95.1% of workflows after requirement clarification, compared with 60.4% using retrieval from the same procedural corpus. Procedural skills improved source recovery across three language models and increased source overlap with analyst code in 13 Mayo Clinic cases. Site-specific adaptation enabled reference-matched cohort execution across eight MIMIC-IV tasks. Within the Mayo Clinic Virtual Trials Program, the framework supported investigator review of cohort construction and endpoint analysis. These findings support coordinating procedural guidance with workflow decisions to improve virtual-trial implementation across complex clinical schemas.

0.10

VITAL: A Framework for Validating Agentic AI in Pharmaceutical Drug Development and Clinical Trial Operations

cs.AI ·2026-11-17 ·Sandeep Burugupalli, Pedro Matos-Filipe, Andrea Hita Ardiaca, Adam Taylor, Alex Grigorenko +8 more
similarity 0.61
Abstract

Current assurance approaches do not establish whether evidence is sufficient to validate, monitor and govern agentic artificial intelligence (AI) within a pharmaceutical context of use. Plausible outputs may conceal failures in retrieval, reasoning, orchestration or human-control points, where reference standards are unavailable. We developed and operationalised VITAL (Validation by Intended use, Traceability, Autonomy and Lifecycle evidence), a validation framework for agents in clinical development, through landscape analysis, regulatory and standards mapping, expert interviews and multi-stakeholder refinement. VITAL integrates context of use, controls, behavioural validation and lifecycle evidence within a risk-adjusted framework. We applied VITAL across epidemiology and treatment-landscape analysis, site selection, enrolment rescue and trial-design trade-off support to translate autonomy, reversibility, transparency and patient impact into proportionate validation activities, evidence requirements and auditable reconstruction of system behaviour. VITAL may inform evidence requirements and lifecycle accountability for higher-risk pharmaceutical uses; evaluation should assess reproducibility across assessors, organisations and system configurations.

0.29

Advancing Clinical Genomic Analysis with a Skill-Centred Agent

cs.AI q-bio.GN ·2026-10-29 ·Qiaoyu Zheng, Weike Zhao, Yanjie Fan, Ye Cao, Mengqi Jiang +8 more
benchmark similarity 0.61
Abstract

Clinical genomic analysis requires experts to integrate evolving guidelines, databases, and computational evidence. As sequencing has become increasingly accessible, this complex and labor-intensive process has become a major bottleneck to the timely use of genomic information in clinical decision-making. To fill this gap, we developed ClinGeX, a large-language-model agent that composes 105 curated executable skills through task-specific retrieval and dependency-aware orchestration. On 223 temporally held-out benchmark cases, ClinGeX achieved 71.7\% macro-averaged task-level concordance with expert reference classifications, compared with 45.7\% for the strongest comparator. In a three-condition, counterbalanced human-AI collaboration study, 45 clinical genomic professionals assessed 135 clinically derived cases under routine (no AI assistance), DeepSeek-assisted and ClinGeX-assisted conditions. ClinGeX assistance increased raw case-level concordance across criterion-level variant analysis, genomic interpretation in rare disease and molecular oncology decision-making (51.1\%, 57.8\%, 64.4\% versus 15.6\%, 31.1\%, 20.0\% in comparator conditions) and reduced reported interpretation time in all scenarios. During an exploratory one-month real-world non-interventional assessment, 11 experienced professionals submitted feedback on 96 self-selected analysis episodes and reported frequent conclusion adoption and time savings. These findings support executable domain skills as a promising approach to augment specialist genomic interpretation.

0.23